SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

20 May 2025 Evaluate
The sales slipped to Rs. 10303.53 millions for the March 2025 quarter as against Rs. 11748.30 millions during the year-ago period.Net profit declined -9.77% to Rs. 2899.99 millions from Rs. 3214.11 millions.Operating profit for the quarter ended March 2025 decreased to 4378.41 millions as compared to 4797.85 millions of corresponding quarter ended March 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 10303.53 11748.30 -12.30 41161.49 41674.28 -1.23 41161.49 41674.28 -1.23
Other Income 437.18 469.55 -6.89 2150.75 1666.66 29.05 2150.75 1666.66 29.05
PBIDT 4378.41 4797.85 -8.74 16576.93 15754.47 5.22 16576.93 15754.47 5.22
Interest 34.46 45.34 -24.00 228.37 78.43 191.18 228.37 78.43 191.18
PBDT 4343.95 4752.51 -8.60 16348.56 15676.04 4.29 16348.56 15676.04 4.29
Depreciation 430.72 425.63 1.20 1692.71 1621.07 4.42 1692.71 1621.07 4.42
PBT 3913.23 4326.88 -9.56 14655.85 14054.97 4.28 14655.85 14054.97 4.28
TAX 1013.24 1112.77 -8.94 3758.32 3621.72 3.77 3758.32 3621.72 3.77
Deferred Tax 22.52 105.98 -78.75 91.24 246.84 -63.04 91.24 246.84 -63.04
PAT 2899.99 3214.11 -9.77 10897.53 10433.25 4.45 10897.53 10433.25 4.45
Equity 164.76 164.71 0.03 164.76 164.71 0.03 164.76 164.71 0.03
PBIDTM(%) 42.49 40.84 4.05 40.27 37.80 6.53 40.27 37.80 6.53

Gland Pharma Share Price

1798.00 0.05 (0.00%)
23-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.85
Dr. Reddys Lab 1333.05
Cipla 1305.85
Zydus Lifesciences 947.10
Lupin 2340.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×